#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0566] The release rate of the anti-mitotic compound from the polymeric material may be varied in, e.g., the manner suggested in column 6 of U.S.
1-1	0-1	[	_	_	
1-2	1-5	0566	_	_	
1-3	5-6	]	_	_	
1-4	7-10	The	_	_	
1-5	11-18	release	_	_	
1-6	19-23	rate	_	_	
1-7	24-26	of	_	_	
1-8	27-30	the	_	_	
1-9	31-43	anti-mitotic	_	_	
1-10	44-52	compound	_	_	
1-11	53-57	from	_	_	
1-12	58-61	the	_	_	
1-13	62-71	polymeric	_	_	
1-14	72-80	material	_	_	
1-15	81-84	may	_	_	
1-16	85-87	be	_	_	
1-17	88-94	varied	_	_	
1-18	95-97	in	_	_	
1-19	97-98	,	_	_	
1-20	99-102	e.g	_	_	
1-21	102-103	.	_	_	
1-22	103-104	,	_	_	
1-23	105-108	the	_	_	
1-24	109-115	manner	_	_	
1-25	116-125	suggested	_	_	
1-26	126-128	in	_	_	
1-27	129-135	column	_	_	
1-28	136-137	6	_	_	
1-29	138-140	of	_	_	
1-30	141-144	U.S	_	_	
1-31	144-145	.	_	_	

#Text=Pat.
2-1	146-149	Pat	_	_	
2-2	149-150	.	_	_	

#Text=No. 5,194,581, the entire disclosure of which is hereby incorporated by reference into this specification.
3-1	151-153	No	_	_	
3-2	153-154	.	_	_	
3-3	155-164	5,194,581	_	_	
3-4	164-165	,	_	_	
3-5	166-169	the	_	_	
3-6	170-176	entire	_	_	
3-7	177-187	disclosure	_	_	
3-8	188-190	of	_	_	
3-9	191-196	which	_	_	
3-10	197-199	is	_	_	
3-11	200-206	hereby	_	_	
3-12	207-219	incorporated	_	_	
3-13	220-222	by	_	_	
3-14	223-232	reference	_	_	
3-15	233-237	into	_	_	
3-16	238-242	this	_	_	
3-17	243-256	specification	_	_	
3-18	256-257	.	_	_	

#Text=As is disclosed in such column 6, "A wide range of degradation rates can be obtained by adjusting the hydrophobicities of the backbones of the polymers and yet the biodegradability is assured.
4-1	258-260	As	_	_	
4-2	261-263	is	_	_	
4-3	264-273	disclosed	_	_	
4-4	274-276	in	_	_	
4-5	277-281	such	_	_	
4-6	282-288	column	_	_	
4-7	289-290	6	_	_	
4-8	290-291	,	_	_	
4-9	292-293	"	_	_	
4-10	293-294	A	_	_	
4-11	295-299	wide	_	_	
4-12	300-305	range	_	_	
4-13	306-308	of	_	_	
4-14	309-320	degradation	_	_	
4-15	321-326	rates	_	_	
4-16	327-330	can	_	_	
4-17	331-333	be	_	_	
4-18	334-342	obtained	_	_	
4-19	343-345	by	_	_	
4-20	346-355	adjusting	_	_	
4-21	356-359	the	_	_	
4-22	360-376	hydrophobicities	_	_	
4-23	377-379	of	_	_	
4-24	380-383	the	_	_	
4-25	384-393	backbones	_	_	
4-26	394-396	of	_	_	
4-27	397-400	the	_	_	
4-28	401-409	polymers	_	_	
4-29	410-413	and	_	_	
4-30	414-417	yet	_	_	
4-31	418-421	the	_	_	
4-32	422-438	biodegradability	_	_	
4-33	439-441	is	_	_	
4-34	442-449	assured	_	_	
4-35	449-450	.	_	_	

#Text=This can be achieved by varying the functional groups R or R'.
5-1	451-455	This	_	_	
5-2	456-459	can	_	_	
5-3	460-462	be	_	_	
5-4	463-471	achieved	_	_	
5-5	472-474	by	_	_	
5-6	475-482	varying	_	_	
5-7	483-486	the	_	_	
5-8	487-497	functional	_	_	
5-9	498-504	groups	_	_	
5-10	505-506	R	_	_	
5-11	507-509	or	_	_	
5-12	510-511	R	_	_	
5-13	511-512	'	_	_	
5-14	512-513	.	_	_	

#Text=The combination of a hydrophobic backbone and a hydrophilic linkage also leads to heterogeneous degradation as cleavage is encouraged, but water penetration is resisted."
6-1	514-517	The	_	_	
6-2	518-529	combination	_	_	
6-3	530-532	of	_	_	
6-4	533-534	a	_	_	
6-5	535-546	hydrophobic	_	_	
6-6	547-555	backbone	_	_	
6-7	556-559	and	_	_	
6-8	560-561	a	_	_	
6-9	562-573	hydrophilic	_	_	
6-10	574-581	linkage	_	_	
6-11	582-586	also	_	_	
6-12	587-592	leads	_	_	
6-13	593-595	to	_	_	
6-14	596-609	heterogeneous	_	_	
6-15	610-621	degradation	_	_	
6-16	622-624	as	_	_	
6-17	625-633	cleavage	_	_	
6-18	634-636	is	_	_	
6-19	637-647	encouraged	_	_	
6-20	647-648	,	_	_	
6-21	649-652	but	_	_	
6-22	653-658	water	_	_	
6-23	659-670	penetration	_	_	
6-24	671-673	is	_	_	
6-25	674-682	resisted	_	_	
6-26	682-683	.	_	_	
6-27	683-684	"	_	_	

#Text=As is disclosed at column 9 of such patent, "The rate of biodegradation of the poly(phosphoester) compositions of the invention may also be controlled by varying the hydrophobicity of the polymer.
7-1	685-687	As	_	_	
7-2	688-690	is	_	_	
7-3	691-700	disclosed	_	_	
7-4	701-703	at	_	_	
7-5	704-710	column	_	_	
7-6	711-712	9	_	_	
7-7	713-715	of	_	_	
7-8	716-720	such	_	_	
7-9	721-727	patent	_	_	
7-10	727-728	,	_	_	
7-11	729-730	"	_	_	
7-12	730-733	The	_	_	
7-13	734-738	rate	_	_	
7-14	739-741	of	_	_	
7-15	742-756	biodegradation	_	_	
7-16	757-759	of	_	_	
7-17	760-763	the	_	_	
7-18	764-768	poly	_	_	
7-19	768-769	(	_	_	
7-20	769-781	phosphoester	_	_	
7-21	781-782	)	_	_	
7-22	783-795	compositions	_	_	
7-23	796-798	of	_	_	
7-24	799-802	the	_	_	
7-25	803-812	invention	_	_	
7-26	813-816	may	_	_	
7-27	817-821	also	_	_	
7-28	822-824	be	_	_	
7-29	825-835	controlled	_	_	
7-30	836-838	by	_	_	
7-31	839-846	varying	_	_	
7-32	847-850	the	_	_	
7-33	851-865	hydrophobicity	_	_	
7-34	866-868	of	_	_	
7-35	869-872	the	_	_	
7-36	873-880	polymer	_	_	
7-37	880-881	.	_	_	

#Text=The mechanism of predictable degradation preferably relies on either group R' in the poly(phosphoester) backbone being hydrophobic for example, an aromatic structure, or, alternatively, if the group R' is not hydrophobic, for example an aliphatic group, then the group R is preferably aromatic.
8-1	882-885	The	_	_	
8-2	886-895	mechanism	_	_	
8-3	896-898	of	_	_	
8-4	899-910	predictable	_	_	
8-5	911-922	degradation	_	_	
8-6	923-933	preferably	_	_	
8-7	934-940	relies	_	_	
8-8	941-943	on	_	_	
8-9	944-950	either	_	_	
8-10	951-956	group	_	_	
8-11	957-958	R	_	_	
8-12	958-959	'	_	_	
8-13	960-962	in	_	_	
8-14	963-966	the	_	_	
8-15	967-971	poly	_	_	
8-16	971-972	(	_	_	
8-17	972-984	phosphoester	_	_	
8-18	984-985	)	_	_	
8-19	986-994	backbone	_	_	
8-20	995-1000	being	_	_	
8-21	1001-1012	hydrophobic	_	_	
8-22	1013-1016	for	_	_	
8-23	1017-1024	example	_	_	
8-24	1024-1025	,	_	_	
8-25	1026-1028	an	_	_	
8-26	1029-1037	aromatic	_	_	
8-27	1038-1047	structure	_	_	
8-28	1047-1048	,	_	_	
8-29	1049-1051	or	_	_	
8-30	1051-1052	,	_	_	
8-31	1053-1066	alternatively	_	_	
8-32	1066-1067	,	_	_	
8-33	1068-1070	if	_	_	
8-34	1071-1074	the	_	_	
8-35	1075-1080	group	_	_	
8-36	1081-1082	R	_	_	
8-37	1082-1083	'	_	_	
8-38	1084-1086	is	_	_	
8-39	1087-1090	not	_	_	
8-40	1091-1102	hydrophobic	_	_	
8-41	1102-1103	,	_	_	
8-42	1104-1107	for	_	_	
8-43	1108-1115	example	_	_	
8-44	1116-1118	an	_	_	
8-45	1119-1128	aliphatic	_	_	
8-46	1129-1134	group	_	_	
8-47	1134-1135	,	_	_	
8-48	1136-1140	then	_	_	
8-49	1141-1144	the	_	_	
8-50	1145-1150	group	_	_	
8-51	1151-1152	R	_	_	
8-52	1153-1155	is	_	_	
8-53	1156-1166	preferably	_	_	
8-54	1167-1175	aromatic	_	_	
8-55	1175-1176	.	_	_	

#Text=The rates of degradation for each poly(phosphoester) composition are generally predictable and constant at a single pH.
9-1	1177-1180	The	_	_	
9-2	1181-1186	rates	_	_	
9-3	1187-1189	of	_	_	
9-4	1190-1201	degradation	_	_	
9-5	1202-1205	for	_	_	
9-6	1206-1210	each	_	_	
9-7	1211-1215	poly	_	_	
9-8	1215-1216	(	_	_	
9-9	1216-1228	phosphoester	_	_	
9-10	1228-1229	)	_	_	
9-11	1230-1241	composition	_	_	
9-12	1242-1245	are	_	_	
9-13	1246-1255	generally	_	_	
9-14	1256-1267	predictable	_	_	
9-15	1268-1271	and	_	_	
9-16	1272-1280	constant	_	_	
9-17	1281-1283	at	_	_	
9-18	1284-1285	a	_	_	
9-19	1286-1292	single	_	_	
9-20	1293-1295	pH	_	_	
9-21	1295-1296	.	_	_	

#Text=This permits the compositions to be introduced into the individual at a variety of tissue sites.
10-1	1297-1301	This	_	_	
10-2	1302-1309	permits	_	_	
10-3	1310-1313	the	_	_	
10-4	1314-1326	compositions	_	_	
10-5	1327-1329	to	_	_	
10-6	1330-1332	be	_	_	
10-7	1333-1343	introduced	_	_	
10-8	1344-1348	into	_	_	
10-9	1349-1352	the	_	_	
10-10	1353-1363	individual	_	_	
10-11	1364-1366	at	_	_	
10-12	1367-1368	a	_	_	
10-13	1369-1376	variety	_	_	
10-14	1377-1379	of	_	_	
10-15	1380-1386	tissue	_	_	
10-16	1387-1392	sites	_	_	
10-17	1392-1393	.	_	_	

#Text=This is especially valuable in that a wide variety of compositions and devices to meet different, but specific, applications may be composed and configured to meet specific demands, dimensions, and shapes--each of which offers individual, but different, predictable periods for degradation.
11-1	1394-1398	This	_	_	
11-2	1399-1401	is	_	_	
11-3	1402-1412	especially	_	_	
11-4	1413-1421	valuable	_	_	
11-5	1422-1424	in	_	_	
11-6	1425-1429	that	_	_	
11-7	1430-1431	a	_	_	
11-8	1432-1436	wide	_	_	
11-9	1437-1444	variety	_	_	
11-10	1445-1447	of	_	_	
11-11	1448-1460	compositions	_	_	
11-12	1461-1464	and	_	_	
11-13	1465-1472	devices	_	_	
11-14	1473-1475	to	_	_	
11-15	1476-1480	meet	_	_	
11-16	1481-1490	different	_	_	
11-17	1490-1491	,	_	_	
11-18	1492-1495	but	_	_	
11-19	1496-1504	specific	_	_	
11-20	1504-1505	,	_	_	
11-21	1506-1518	applications	_	_	
11-22	1519-1522	may	_	_	
11-23	1523-1525	be	_	_	
11-24	1526-1534	composed	_	_	
11-25	1535-1538	and	_	_	
11-26	1539-1549	configured	_	_	
11-27	1550-1552	to	_	_	
11-28	1553-1557	meet	_	_	
11-29	1558-1566	specific	_	_	
11-30	1567-1574	demands	_	_	
11-31	1574-1575	,	_	_	
11-32	1576-1586	dimensions	_	_	
11-33	1586-1587	,	_	_	
11-34	1588-1591	and	_	_	
11-35	1592-1598	shapes	_	_	
11-36	1598-1599	-	_	_	
11-37	1599-1600	-	_	_	
11-38	1600-1604	each	_	_	
11-39	1605-1607	of	_	_	
11-40	1608-1613	which	_	_	
11-41	1614-1620	offers	_	_	
11-42	1621-1631	individual	_	_	
11-43	1631-1632	,	_	_	
11-44	1633-1636	but	_	_	
11-45	1637-1646	different	_	_	
11-46	1646-1647	,	_	_	
11-47	1648-1659	predictable	_	_	
11-48	1660-1667	periods	_	_	
11-49	1668-1671	for	_	_	
11-50	1672-1683	degradation	_	_	
11-51	1683-1684	.	_	_	

#Text=When the composition of the invention is used for long term delivery of a anti-mitotic compound a relatively hydrophobic backbone matrix, for example, containing bisphenol A, is preferred.
12-1	1685-1689	When	_	_	
12-2	1690-1693	the	_	_	
12-3	1694-1705	composition	_	_	
12-4	1706-1708	of	_	_	
12-5	1709-1712	the	_	_	
12-6	1713-1722	invention	_	_	
12-7	1723-1725	is	_	_	
12-8	1726-1730	used	_	_	
12-9	1731-1734	for	_	_	
12-10	1735-1739	long	_	_	
12-11	1740-1744	term	_	_	
12-12	1745-1753	delivery	_	_	
12-13	1754-1756	of	_	_	
12-14	1757-1758	a	_	_	
12-15	1759-1771	anti-mitotic	_	_	
12-16	1772-1780	compound	_	_	
12-17	1781-1782	a	_	_	
12-18	1783-1793	relatively	_	_	
12-19	1794-1805	hydrophobic	_	_	
12-20	1806-1814	backbone	_	_	
12-21	1815-1821	matrix	_	_	
12-22	1821-1822	,	_	_	
12-23	1823-1826	for	_	_	
12-24	1827-1834	example	_	_	
12-25	1834-1835	,	_	_	
12-26	1836-1846	containing	_	_	
12-27	1847-1856	bisphenol	_	_	
12-28	1857-1858	A	_	_	
12-29	1858-1859	,	_	_	
12-30	1860-1862	is	_	_	
12-31	1863-1872	preferred	_	_	
12-32	1872-1873	.	_	_	

#Text=It is possible to enhance the degradation rate of the poly(phosphoester) or shorten the functional life of the device, by introducing hydrophilic or polar groups, into the backbone matrix.
13-1	1874-1876	It	_	_	
13-2	1877-1879	is	_	_	
13-3	1880-1888	possible	_	_	
13-4	1889-1891	to	_	_	
13-5	1892-1899	enhance	_	_	
13-6	1900-1903	the	_	_	
13-7	1904-1915	degradation	_	_	
13-8	1916-1920	rate	_	_	
13-9	1921-1923	of	_	_	
13-10	1924-1927	the	_	_	
13-11	1928-1932	poly	_	_	
13-12	1932-1933	(	_	_	
13-13	1933-1945	phosphoester	_	_	
13-14	1945-1946	)	_	_	
13-15	1947-1949	or	_	_	
13-16	1950-1957	shorten	_	_	
13-17	1958-1961	the	_	_	
13-18	1962-1972	functional	_	_	
13-19	1973-1977	life	_	_	
13-20	1978-1980	of	_	_	
13-21	1981-1984	the	_	_	
13-22	1985-1991	device	_	_	
13-23	1991-1992	,	_	_	
13-24	1993-1995	by	_	_	
13-25	1996-2007	introducing	_	_	
13-26	2008-2019	hydrophilic	_	_	
13-27	2020-2022	or	_	_	
13-28	2023-2028	polar	_	_	
13-29	2029-2035	groups	_	_	
13-30	2035-2036	,	_	_	
13-31	2037-2041	into	_	_	
13-32	2042-2045	the	_	_	
13-33	2046-2054	backbone	_	_	
13-34	2055-2061	matrix	_	_	
13-35	2061-2062	.	_	_	

#Text=Further, the introduction of methylene groups into the backbone matrix will usually increase the flexibility of the backbone and decrease the crystallinity of the polymer.
14-1	2063-2070	Further	_	_	
14-2	2070-2071	,	_	_	
14-3	2072-2075	the	_	_	
14-4	2076-2088	introduction	_	_	
14-5	2089-2091	of	_	_	
14-6	2092-2101	methylene	_	_	
14-7	2102-2108	groups	_	_	
14-8	2109-2113	into	_	_	
14-9	2114-2117	the	_	_	
14-10	2118-2126	backbone	_	_	
14-11	2127-2133	matrix	_	_	
14-12	2134-2138	will	_	_	
14-13	2139-2146	usually	_	_	
14-14	2147-2155	increase	_	_	
14-15	2156-2159	the	_	_	
14-16	2160-2171	flexibility	_	_	
14-17	2172-2174	of	_	_	
14-18	2175-2178	the	_	_	
14-19	2179-2187	backbone	_	_	
14-20	2188-2191	and	_	_	
14-21	2192-2200	decrease	_	_	
14-22	2201-2204	the	_	_	
14-23	2205-2218	crystallinity	_	_	
14-24	2219-2221	of	_	_	
14-25	2222-2225	the	_	_	
14-26	2226-2233	polymer	_	_	
14-27	2233-2234	.	_	_	

#Text=Conversely, to obtain a more rigid backbone matrix, for example, when used orthopedically, an aromatic structure, such as a diphenyl group, can be incorporated into the matrix.
15-1	2235-2245	Conversely	_	_	
15-2	2245-2246	,	_	_	
15-3	2247-2249	to	_	_	
15-4	2250-2256	obtain	_	_	
15-5	2257-2258	a	_	_	
15-6	2259-2263	more	_	_	
15-7	2264-2269	rigid	_	_	
15-8	2270-2278	backbone	_	_	
15-9	2279-2285	matrix	_	_	
15-10	2285-2286	,	_	_	
15-11	2287-2290	for	_	_	
15-12	2291-2298	example	_	_	
15-13	2298-2299	,	_	_	
15-14	2300-2304	when	_	_	
15-15	2305-2309	used	_	_	
15-16	2310-2324	orthopedically	_	_	
15-17	2324-2325	,	_	_	
15-18	2326-2328	an	_	_	
15-19	2329-2337	aromatic	_	_	
15-20	2338-2347	structure	_	_	
15-21	2347-2348	,	_	_	
15-22	2349-2353	such	_	_	
15-23	2354-2356	as	_	_	
15-24	2357-2358	a	_	_	
15-25	2359-2367	diphenyl	_	_	
15-26	2368-2373	group	_	_	
15-27	2373-2374	,	_	_	
15-28	2375-2378	can	_	_	
15-29	2379-2381	be	_	_	
15-30	2382-2394	incorporated	_	_	
15-31	2395-2399	into	_	_	
15-32	2400-2403	the	_	_	
15-33	2404-2410	matrix	_	_	
15-34	2410-2411	.	_	_	

#Text=Also, the poly(phosphoester) can be crosslinked, for example, using 1,3,5-trihydroxybenzene or (CH2 OH)4C, to enhance the modulus of the polymer.
16-1	2412-2416	Also	_	_	
16-2	2416-2417	,	_	_	
16-3	2418-2421	the	_	_	
16-4	2422-2426	poly	_	_	
16-5	2426-2427	(	_	_	
16-6	2427-2439	phosphoester	_	_	
16-7	2439-2440	)	_	_	
16-8	2441-2444	can	_	_	
16-9	2445-2447	be	_	_	
16-10	2448-2459	crosslinked	_	_	
16-11	2459-2460	,	_	_	
16-12	2461-2464	for	_	_	
16-13	2465-2472	example	_	_	
16-14	2472-2473	,	_	_	
16-15	2474-2479	using	_	_	
16-16	2480-2485	1,3,5	_	_	
16-17	2485-2486	-	_	_	
16-18	2486-2503	trihydroxybenzene	_	_	
16-19	2504-2506	or	_	_	
16-20	2507-2508	(	_	_	
16-21	2508-2511	CH2	_	_	
16-22	2512-2514	OH	_	_	
16-23	2514-2515	)	_	_	
16-24	2515-2517	4C	_	_	
16-25	2517-2518	,	_	_	
16-26	2519-2521	to	_	_	
16-27	2522-2529	enhance	_	_	
16-28	2530-2533	the	_	_	
16-29	2534-2541	modulus	_	_	
16-30	2542-2544	of	_	_	
16-31	2545-2548	the	_	_	
16-32	2549-2556	polymer	_	_	
16-33	2556-2557	.	_	_	

#Text=Similar considerations hold for the structure of the side chain (R)."
#Text=[0567] By way of yet further illustration, and referring to U.S.
17-1	2558-2565	Similar	_	_	
17-2	2566-2580	considerations	_	_	
17-3	2581-2585	hold	_	_	
17-4	2586-2589	for	_	_	
17-5	2590-2593	the	_	_	
17-6	2594-2603	structure	_	_	
17-7	2604-2606	of	_	_	
17-8	2607-2610	the	_	_	
17-9	2611-2615	side	_	_	
17-10	2616-2621	chain	_	_	
17-11	2622-2623	(	_	_	
17-12	2623-2624	R	_	_	
17-13	2624-2625	)	_	_	
17-14	2625-2626	.	_	_	
17-15	2626-2627	"	_	_	
17-16	2628-2629	[	_	_	
17-17	2629-2633	0567	_	_	
17-18	2633-2634	]	_	_	
17-19	2635-2637	By	_	_	
17-20	2638-2641	way	_	_	
17-21	2642-2644	of	_	_	
17-22	2645-2648	yet	_	_	
17-23	2649-2656	further	_	_	
17-24	2657-2669	illustration	_	_	
17-25	2669-2670	,	_	_	
17-26	2671-2674	and	_	_	
17-27	2675-2684	referring	_	_	
17-28	2685-2687	to	_	_	
17-29	2688-2691	U.S	_	_	
17-30	2691-2692	.	_	_	

#Text=Pat.
18-1	2693-2696	Pat	_	_	
18-2	2696-2697	.	_	_	

#Text=No. 5,252,713 (the entire disclosure of which is hereby incorporated by reference into this specification), the polymeric material may be a polypeptide comprising at least one drug-binding domain that non-covalently binds a drug.
19-1	2698-2700	No	_	_	
19-2	2700-2701	.	_	_	
19-3	2702-2711	5,252,713	_	_	
19-4	2712-2713	(	_	_	
19-5	2713-2716	the	_	_	
19-6	2717-2723	entire	_	_	
19-7	2724-2734	disclosure	_	_	
19-8	2735-2737	of	_	_	
19-9	2738-2743	which	_	_	
19-10	2744-2746	is	_	_	
19-11	2747-2753	hereby	_	_	
19-12	2754-2766	incorporated	_	_	
19-13	2767-2769	by	_	_	
19-14	2770-2779	reference	_	_	
19-15	2780-2784	into	_	_	
19-16	2785-2789	this	_	_	
19-17	2790-2803	specification	_	_	
19-18	2803-2804	)	_	_	
19-19	2804-2805	,	_	_	
19-20	2806-2809	the	_	_	
19-21	2810-2819	polymeric	_	_	
19-22	2820-2828	material	_	_	
19-23	2829-2832	may	_	_	
19-24	2833-2835	be	_	_	
19-25	2836-2837	a	_	_	
19-26	2838-2849	polypeptide	_	_	
19-27	2850-2860	comprising	_	_	
19-28	2861-2863	at	_	_	
19-29	2864-2869	least	_	_	
19-30	2870-2873	one	_	_	
19-31	2874-2886	drug-binding	_	_	
19-32	2887-2893	domain	_	_	
19-33	2894-2898	that	_	_	
19-34	2899-2913	non-covalently	_	_	
19-35	2914-2919	binds	_	_	
19-36	2920-2921	a	_	_	
19-37	2922-2926	drug	_	_	
19-38	2926-2927	.	_	_	

#Text=The means of identifying and isolating such a polypeptide is described at columns 5-7 of the patent, wherein it is disclosed that: "The process of isolating a polymeric carrier from a drug-binding, large molecular weight protein begins with the identification of a large protein that can non-covalently bind the drug of interest.
20-1	2928-2931	The	_	_	
20-2	2932-2937	means	_	_	
20-3	2938-2940	of	_	_	
20-4	2941-2952	identifying	_	_	
20-5	2953-2956	and	_	_	
20-6	2957-2966	isolating	_	_	
20-7	2967-2971	such	_	_	
20-8	2972-2973	a	_	_	
20-9	2974-2985	polypeptide	_	_	
20-10	2986-2988	is	_	_	
20-11	2989-2998	described	_	_	
20-12	2999-3001	at	_	_	
20-13	3002-3009	columns	_	_	
20-14	3010-3011	5	_	_	
20-15	3011-3012	-	_	_	
20-16	3012-3013	7	_	_	
20-17	3014-3016	of	_	_	
20-18	3017-3020	the	_	_	
20-19	3021-3027	patent	_	_	
20-20	3027-3028	,	_	_	
20-21	3029-3036	wherein	_	_	
20-22	3037-3039	it	_	_	
20-23	3040-3042	is	_	_	
20-24	3043-3052	disclosed	_	_	
20-25	3053-3057	that	_	_	
20-26	3057-3058	:	_	_	
20-27	3059-3060	"	_	_	
20-28	3060-3063	The	_	_	
20-29	3064-3071	process	_	_	
20-30	3072-3074	of	_	_	
20-31	3075-3084	isolating	_	_	
20-32	3085-3086	a	_	_	
20-33	3087-3096	polymeric	_	_	
20-34	3097-3104	carrier	_	_	
20-35	3105-3109	from	_	_	
20-36	3110-3111	a	_	_	
20-37	3112-3124	drug-binding	_	_	
20-38	3124-3125	,	_	_	
20-39	3126-3131	large	_	_	
20-40	3132-3141	molecular	_	_	
20-41	3142-3148	weight	_	_	
20-42	3149-3156	protein	_	_	
20-43	3157-3163	begins	_	_	
20-44	3164-3168	with	_	_	
20-45	3169-3172	the	_	_	
20-46	3173-3187	identification	_	_	
20-47	3188-3190	of	_	_	
20-48	3191-3192	a	_	_	
20-49	3193-3198	large	_	_	
20-50	3199-3206	protein	_	_	
20-51	3207-3211	that	_	_	
20-52	3212-3215	can	_	_	
20-53	3216-3230	non-covalently	_	_	
20-54	3231-3235	bind	_	_	
20-55	3236-3239	the	_	_	
20-56	3240-3244	drug	_	_	
20-57	3245-3247	of	_	_	
20-58	3248-3256	interest	_	_	
20-59	3256-3257	.	_	_	

#Text=Examples of such protein/drug pairs are shown in Table I.
21-1	3258-3266	Examples	_	_	
21-2	3267-3269	of	_	_	
21-3	3270-3274	such	_	_	
21-4	3275-3282	protein	_	_	
21-5	3282-3283	/	_	_	
21-6	3283-3287	drug	_	_	
21-7	3288-3293	pairs	_	_	
21-8	3294-3297	are	_	_	
21-9	3298-3303	shown	_	_	
21-10	3304-3306	in	_	_	
21-11	3307-3312	Table	_	_	
21-12	3313-3314	I	_	_	
21-13	3314-3315	.	_	_	

#Text=The drugs in the Table (other than the steroids) are anti-cancer drugs . . . "
#Text=[0568] As is also disclosed in U.S.
22-1	3316-3319	The	_	_	
22-2	3320-3325	drugs	_	_	
22-3	3326-3328	in	_	_	
22-4	3329-3332	the	_	_	
22-5	3333-3338	Table	_	_	
22-6	3339-3340	(	_	_	
22-7	3340-3345	other	_	_	
22-8	3346-3350	than	_	_	
22-9	3351-3354	the	_	_	
22-10	3355-3363	steroids	_	_	
22-11	3363-3364	)	_	_	
22-12	3365-3368	are	_	_	
22-13	3369-3380	anti-cancer	_	_	
22-14	3381-3386	drugs	_	_	
22-15	3387-3388	.	_	_	
22-16	3389-3390	.	_	_	
22-17	3391-3392	.	_	_	
22-18	3393-3394	"	_	_	
22-19	3395-3396	[	_	_	
22-20	3396-3400	0568	_	_	
22-21	3400-3401	]	_	_	
22-22	3402-3404	As	_	_	
22-23	3405-3407	is	_	_	
22-24	3408-3412	also	_	_	
22-25	3413-3422	disclosed	_	_	
22-26	3423-3425	in	_	_	
22-27	3426-3429	U.S	_	_	
22-28	3429-3430	.	_	_	

#Text=Pat.
23-1	3431-3434	Pat	_	_	
23-2	3434-3435	.	_	_	

#Text=No. 5,252,713, "Other drug-binding proteins may be identified by appropriate analytical procedures, including Western blotting of large proteins or protein fragments and subsequent incubation with a detectable form of drug.
24-1	3436-3438	No	_	_	
24-2	3438-3439	.	_	_	
24-3	3440-3449	5,252,713	_	_	
24-4	3449-3450	,	_	_	
24-5	3451-3452	"	_	_	
24-6	3452-3457	Other	_	_	
24-7	3458-3470	drug-binding	_	_	
24-8	3471-3479	proteins	_	_	
24-9	3480-3483	may	_	_	
24-10	3484-3486	be	_	_	
24-11	3487-3497	identified	_	_	
24-12	3498-3500	by	_	_	
24-13	3501-3512	appropriate	_	_	
24-14	3513-3523	analytical	_	_	
24-15	3524-3534	procedures	_	_	
24-16	3534-3535	,	_	_	
24-17	3536-3545	including	_	_	
24-18	3546-3553	Western	_	_	
24-19	3554-3562	blotting	_	_	
24-20	3563-3565	of	_	_	
24-21	3566-3571	large	_	_	
24-22	3572-3580	proteins	_	_	
24-23	3581-3583	or	_	_	
24-24	3584-3591	protein	_	_	
24-25	3592-3601	fragments	_	_	
24-26	3602-3605	and	_	_	
24-27	3606-3616	subsequent	_	_	
24-28	3617-3627	incubation	_	_	
24-29	3628-3632	with	_	_	
24-30	3633-3634	a	_	_	
24-31	3635-3645	detectable	_	_	
24-32	3646-3650	form	_	_	
24-33	3651-3653	of	_	_	
24-34	3654-3658	drug	_	_	
24-35	3658-3659	.	_	_	

#Text=Alternative procedures include combining a drug and a protein in a solution, followed by size exclusion HPLC gel filtration, thin-layer chromatography (TLC), or other analytical procedures that can discriminate between free and protein-bound drug.
25-1	3660-3671	Alternative	*[1]	29-16[2_1]	
25-2	3672-3682	procedures	*[1]	_	
25-3	3683-3690	include	*[1]	_	
25-4	3691-3700	combining	*[1]	_	
25-5	3701-3702	a	*[1]	_	
25-6	3703-3707	drug	*[1]	_	
25-7	3708-3711	and	*[1]	_	
25-8	3712-3713	a	*[1]	_	
25-9	3714-3721	protein	*[1]	_	
25-10	3722-3724	in	*[1]	_	
25-11	3725-3726	a	*[1]	_	
25-12	3727-3735	solution	*[1]	_	
25-13	3735-3736	,	*[1]	_	
25-14	3737-3745	followed	*[1]	_	
25-15	3746-3748	by	*[1]	_	
25-16	3749-3753	size	*[1]	_	
25-17	3754-3763	exclusion	*[1]	_	
25-18	3764-3768	HPLC	*[1]	_	
25-19	3769-3772	gel	*[1]	_	
25-20	3773-3783	filtration	*[1]	_	
25-21	3783-3784	,	*[1]	_	
25-22	3785-3795	thin-layer	*[1]	_	
25-23	3796-3810	chromatography	*[1]	_	
25-24	3811-3812	(	*[1]	_	
25-25	3812-3815	TLC	*[1]	_	
25-26	3815-3816	)	*[1]	_	
25-27	3816-3817	,	*[1]	_	
25-28	3818-3820	or	*[1]	_	
25-29	3821-3826	other	*[1]	_	
25-30	3827-3837	analytical	*[1]	_	
25-31	3838-3848	procedures	*[1]	_	
25-32	3849-3853	that	*[1]	_	
25-33	3854-3857	can	*[1]	_	
25-34	3858-3870	discriminate	*[1]	_	
25-35	3871-3878	between	*[1]	_	
25-36	3879-3883	free	*[1]	_	
25-37	3884-3887	and	*[1]	_	
25-38	3888-3901	protein-bound	*[1]	_	
25-39	3902-3906	drug	*[1]	_	
25-40	3906-3907	.	*[1]	_	

#Text=Detection of drug binding can be accomplished by using radiolabeled, fluorescent, or colored drugs and appropriate detection methods.
26-1	3908-3917	Detection	*[1]	_	
26-2	3918-3920	of	*[1]	_	
26-3	3921-3925	drug	*[1]	_	
26-4	3926-3933	binding	*[1]	_	
26-5	3934-3937	can	*[1]	_	
26-6	3938-3940	be	*[1]	_	
26-7	3941-3953	accomplished	*[1]	_	
26-8	3954-3956	by	*[1]	_	
26-9	3957-3962	using	*[1]	_	
26-10	3963-3975	radiolabeled	*[1]	_	
26-11	3975-3976	,	*[1]	_	
26-12	3977-3988	fluorescent	*[1]	_	
26-13	3988-3989	,	*[1]	_	
26-14	3990-3992	or	*[1]	_	
26-15	3993-4000	colored	*[1]	_	
26-16	4001-4006	drugs	*[1]	_	
26-17	4007-4010	and	*[1]	_	
26-18	4011-4022	appropriate	*[1]	_	
26-19	4023-4032	detection	*[1]	_	
26-20	4033-4040	methods	*[1]	_	
26-21	4040-4041	.	*[1]	_	

#Text=Equilibrium dialysis with labeled drug may be used.
27-1	4042-4053	Equilibrium	*[1]	_	
27-2	4054-4062	dialysis	*[1]	_	
27-3	4063-4067	with	*[1]	_	
27-4	4068-4075	labeled	*[1]	_	
27-5	4076-4080	drug	*[1]	_	
27-6	4081-4084	may	*[1]	_	
27-7	4085-4087	be	*[1]	_	
27-8	4088-4092	used	*[1]	_	
27-9	4092-4093	.	*[1]	_	

#Text=Alternative methods include monitoring the fluorescence change that occurs upon binding of certain drugs (e.g., anthracyclines or analogs thereof, which should be fluorescent) . . . ".
28-1	4094-4105	Alternative	*[1]	_	
28-2	4106-4113	methods	*[1]	_	
28-3	4114-4121	include	*[1]	_	
28-4	4122-4132	monitoring	*[1]	_	
28-5	4133-4136	the	*[1]	_	
28-6	4137-4149	fluorescence	*[1]	_	
28-7	4150-4156	change	*[1]	_	
28-8	4157-4161	that	*[1]	_	
28-9	4162-4168	occurs	*[1]	_	
28-10	4169-4173	upon	*[1]	_	
28-11	4174-4181	binding	*[1]	_	
28-12	4182-4184	of	*[1]	_	
28-13	4185-4192	certain	*[1]	_	
28-14	4193-4198	drugs	*[1]	_	
28-15	4199-4200	(	*[1]	_	
28-16	4200-4203	e.g	*[1]	_	
28-17	4203-4204	.	*[1]	_	
28-18	4204-4205	,	*[1]	_	
28-19	4206-4220	anthracyclines	*[1]	_	
28-20	4221-4223	or	*[1]	_	
28-21	4224-4231	analogs	*[1]	_	
28-22	4232-4239	thereof	*[1]	_	
28-23	4239-4240	,	*[1]	_	
28-24	4241-4246	which	*[1]	_	
28-25	4247-4253	should	*[1]	_	
28-26	4254-4256	be	*[1]	_	
28-27	4257-4268	fluorescent	*[1]	_	
28-28	4268-4269	)	*[1]	_	
28-29	4270-4271	.	*[1]	_	
28-30	4272-4273	.	*[1]	_	
28-31	4274-4275	.	*[1]	_	
28-32	4276-4277	"	*[1]	_	
28-33	4277-4278	.	*[1]	_	

#Text=In one detection method, drug and protein are mixed, and an aliquot of this solution (not exceeding 5% of the column volume of an HPLC column, such as a Bio-sil TSK-250 7.5x30 cm column) is loaded onto the HPLC column.
29-1	4279-4281	In	_	_	
29-2	4282-4285	one	_	_	
29-3	4286-4295	detection	_	_	
29-4	4296-4302	method	_	_	
29-5	4302-4303	,	_	_	
29-6	4304-4308	drug	_	_	
29-7	4309-4312	and	_	_	
29-8	4313-4320	protein	_	_	
29-9	4321-4324	are	_	_	
29-10	4325-4330	mixed	_	_	
29-11	4330-4331	,	_	_	
29-12	4332-4335	and	_	_	
29-13	4336-4338	an	_	_	
29-14	4339-4346	aliquot	_	_	
29-15	4347-4349	of	_	_	
29-16	4350-4354	this	*[2]	_	
29-17	4355-4363	solution	*[2]	_	
29-18	4364-4365	(	_	_	
29-19	4365-4368	not	_	_	
29-20	4369-4378	exceeding	_	_	
29-21	4379-4381	5%	_	_	
29-22	4382-4384	of	_	_	
29-23	4385-4388	the	_	_	
29-24	4389-4395	column	_	_	
29-25	4396-4402	volume	_	_	
29-26	4403-4405	of	_	_	
29-27	4406-4408	an	_	_	
29-28	4409-4413	HPLC	_	_	
29-29	4414-4420	column	_	_	
29-30	4420-4421	,	_	_	
29-31	4422-4426	such	_	_	
29-32	4427-4429	as	_	_	
29-33	4430-4431	a	_	_	
29-34	4432-4439	Bio-sil	_	_	
29-35	4440-4443	TSK	_	_	
29-36	4443-4444	-	_	_	
29-37	4444-4447	250	_	_	
29-38	4448-4454	7.5x30	_	_	
29-39	4455-4457	cm	_	_	
29-40	4458-4464	column	_	_	
29-41	4464-4465	)	_	_	
29-42	4466-4468	is	_	_	
29-43	4469-4475	loaded	_	_	
29-44	4476-4480	onto	_	_	
29-45	4481-4484	the	_	_	
29-46	4485-4489	HPLC	_	_	
29-47	4490-4496	column	_	_	
29-48	4496-4497	.	_	_	

#Text=The flow rate is 1 ml/min.
30-1	4498-4501	The	_	_	
30-2	4502-4506	flow	_	_	
30-3	4507-4511	rate	_	_	
30-4	4512-4514	is	_	_	
30-5	4515-4516	1	_	_	
30-6	4517-4519	ml	_	_	
30-7	4519-4520	/	_	_	
30-8	4520-4523	min	_	_	
30-9	4523-4524	.	_	_	

#Text=The drug bound to protein will elute first, in a separate peak, followed by free drug, eluting at a position characteristic of its molecular weight.
31-1	4525-4528	The	_	_	
31-2	4529-4533	drug	_	_	
31-3	4534-4539	bound	_	_	
31-4	4540-4542	to	_	_	
31-5	4543-4550	protein	_	_	
31-6	4551-4555	will	_	_	
31-7	4556-4561	elute	_	_	
31-8	4562-4567	first	_	_	
31-9	4567-4568	,	_	_	
31-10	4569-4571	in	_	_	
31-11	4572-4573	a	_	_	
31-12	4574-4582	separate	_	_	
31-13	4583-4587	peak	_	_	
31-14	4587-4588	,	_	_	
31-15	4589-4597	followed	_	_	
31-16	4598-4600	by	_	_	
31-17	4601-4605	free	_	_	
31-18	4606-4610	drug	_	_	
31-19	4610-4611	,	_	_	
31-20	4612-4619	eluting	_	_	
31-21	4620-4622	at	_	_	
31-22	4623-4624	a	_	_	
31-23	4625-4633	position	_	_	
31-24	4634-4648	characteristic	_	_	
31-25	4649-4651	of	_	_	
31-26	4652-4655	its	_	_	
31-27	4656-4665	molecular	_	_	
31-28	4666-4672	weight	_	_	
31-29	4672-4673	.	_	_	

#Text=If the drug is doxorubicin, both a 280-nm as well as a 495-nm adsorptive peak will correspond to the elution position of the protein if interaction occurs.
32-1	4674-4676	If	_	_	
32-2	4677-4680	the	_	_	
32-3	4681-4685	drug	_	_	
32-4	4686-4688	is	_	_	
32-5	4689-4700	doxorubicin	_	_	
32-6	4700-4701	,	_	_	
32-7	4702-4706	both	_	_	
32-8	4707-4708	a	_	_	
32-9	4709-4712	280	_	_	
32-10	4712-4713	-	_	_	
32-11	4713-4715	nm	_	_	
32-12	4716-4718	as	_	_	
32-13	4719-4723	well	_	_	
32-14	4724-4726	as	_	_	
32-15	4727-4728	a	_	_	
32-16	4729-4732	495	_	_	
32-17	4732-4733	-	_	_	
32-18	4733-4735	nm	_	_	
32-19	4736-4746	adsorptive	_	_	
32-20	4747-4751	peak	_	_	
32-21	4752-4756	will	_	_	
32-22	4757-4767	correspond	_	_	
32-23	4768-4770	to	_	_	
32-24	4771-4774	the	_	_	
32-25	4775-4782	elution	_	_	
32-26	4783-4791	position	_	_	
32-27	4792-4794	of	_	_	
32-28	4795-4798	the	_	_	
32-29	4799-4806	protein	_	_	
32-30	4807-4809	if	_	_	
32-31	4810-4821	interaction	_	_	
32-32	4822-4828	occurs	_	_	
32-33	4828-4829	.	_	_	

#Text=The elution peaks for other drugs will indicate whether drug binding occurs . . . ."
#Text=[0569] As is also disclosed in U.S.
33-1	4830-4833	The	_	_	
33-2	4834-4841	elution	_	_	
33-3	4842-4847	peaks	_	_	
33-4	4848-4851	for	_	_	
33-5	4852-4857	other	_	_	
33-6	4858-4863	drugs	_	_	
33-7	4864-4868	will	_	_	
33-8	4869-4877	indicate	_	_	
33-9	4878-4885	whether	_	_	
33-10	4886-4890	drug	_	_	
33-11	4891-4898	binding	_	_	
33-12	4899-4905	occurs	_	_	
33-13	4906-4907	.	_	_	
33-14	4908-4909	.	_	_	
33-15	4910-4911	.	_	_	
33-16	4912-4913	.	_	_	
33-17	4913-4914	"	_	_	
33-18	4915-4916	[	_	_	
33-19	4916-4920	0569	_	_	
33-20	4920-4921	]	_	_	
33-21	4922-4924	As	_	_	
33-22	4925-4927	is	_	_	
33-23	4928-4932	also	_	_	
33-24	4933-4942	disclosed	_	_	
33-25	4943-4945	in	_	_	
33-26	4946-4949	U.S	_	_	
33-27	4949-4950	.	_	_	

#Text=Pat.
34-1	4951-4954	Pat	_	_	
34-2	4954-4955	.	_	_	

#Text=No. 5,252,713, "Knowledge of the chemical structure of a particular drug (i.e., whether chemically reactive functional groups are present) allows one to predict whether covalent binding of the drug to a given protein can occur.
35-1	4956-4958	No	_	_	
35-2	4958-4959	.	_	_	
35-3	4960-4969	5,252,713	_	_	
35-4	4969-4970	,	_	_	
35-5	4971-4972	"	_	_	
35-6	4972-4981	Knowledge	_	_	
35-7	4982-4984	of	_	_	
35-8	4985-4988	the	_	_	
35-9	4989-4997	chemical	_	_	
35-10	4998-5007	structure	_	_	
35-11	5008-5010	of	_	_	
35-12	5011-5012	a	_	_	
35-13	5013-5023	particular	_	_	
35-14	5024-5028	drug	_	_	
35-15	5029-5030	(	_	_	
35-16	5030-5033	i.e	_	_	
35-17	5033-5034	.	_	_	
35-18	5034-5035	,	_	_	
35-19	5036-5043	whether	_	_	
35-20	5044-5054	chemically	_	_	
35-21	5055-5063	reactive	_	_	
35-22	5064-5074	functional	_	_	
35-23	5075-5081	groups	_	_	
35-24	5082-5085	are	_	_	
35-25	5086-5093	present	_	_	
35-26	5093-5094	)	_	_	
35-27	5095-5101	allows	_	_	
35-28	5102-5105	one	_	_	
35-29	5106-5108	to	_	_	
35-30	5109-5116	predict	_	_	
35-31	5117-5124	whether	_	_	
35-32	5125-5133	covalent	_	_	
35-33	5134-5141	binding	_	_	
35-34	5142-5144	of	_	_	
35-35	5145-5148	the	_	_	
35-36	5149-5153	drug	_	_	
35-37	5154-5156	to	_	_	
35-38	5157-5158	a	_	_	
35-39	5159-5164	given	_	_	
35-40	5165-5172	protein	_	_	
35-41	5173-5176	can	_	_	
35-42	5177-5182	occur	_	_	
35-43	5182-5183	.	_	_	

#Text=Additional methods for determining whether drug binding is covalent or non-covalent include incubating the drug with the protein, followed by dialysis or subjecting the protein to denaturing conditions.
36-1	5184-5194	Additional	_	_	
36-2	5195-5202	methods	_	_	
36-3	5203-5206	for	_	_	
36-4	5207-5218	determining	_	_	
36-5	5219-5226	whether	_	_	
36-6	5227-5231	drug	_	_	
36-7	5232-5239	binding	_	_	
36-8	5240-5242	is	_	_	
36-9	5243-5251	covalent	_	_	
36-10	5252-5254	or	_	_	
36-11	5255-5267	non-covalent	_	_	
36-12	5268-5275	include	_	_	
36-13	5276-5286	incubating	_	_	
36-14	5287-5290	the	_	_	
36-15	5291-5295	drug	_	_	
36-16	5296-5300	with	_	_	
36-17	5301-5304	the	_	_	
36-18	5305-5312	protein	_	_	
36-19	5312-5313	,	_	_	
36-20	5314-5322	followed	_	_	
36-21	5323-5325	by	_	_	
36-22	5326-5334	dialysis	_	_	
36-23	5335-5337	or	_	_	
36-24	5338-5348	subjecting	_	_	
36-25	5349-5352	the	_	_	
36-26	5353-5360	protein	_	_	
36-27	5361-5363	to	_	_	
36-28	5364-5374	denaturing	_	_	
36-29	5375-5385	conditions	_	_	
36-30	5385-5386	.	_	_	

#Text=Release of the drug from the drug-binding protein during these procedures indicates that the drug was non-covalently bound.
37-1	5387-5394	Release	_	_	
37-2	5395-5397	of	_	_	
37-3	5398-5401	the	_	_	
37-4	5402-5406	drug	_	_	
37-5	5407-5411	from	_	_	
37-6	5412-5415	the	_	_	
37-7	5416-5428	drug-binding	_	_	
37-8	5429-5436	protein	_	_	
37-9	5437-5443	during	_	_	
37-10	5444-5449	these	_	_	
37-11	5450-5460	procedures	_	_	
37-12	5461-5470	indicates	_	_	
37-13	5471-5475	that	_	_	
37-14	5476-5479	the	_	_	
37-15	5480-5484	drug	_	_	
37-16	5485-5488	was	_	_	
37-17	5489-5503	non-covalently	_	_	
37-18	5504-5509	bound	_	_	
37-19	5509-5510	.	_	_	

#Text=Usually, a dissociation constant of about 10-15 M or less indicates covalent or extremely tight non-covalent binding . . . ."
#Text=[0570] As is also disclosed in U.S.
38-1	5511-5518	Usually	_	_	
38-2	5518-5519	,	_	_	
38-3	5520-5521	a	_	_	
38-4	5522-5534	dissociation	_	_	
38-5	5535-5543	constant	_	_	
38-6	5544-5546	of	_	_	
38-7	5547-5552	about	_	_	
38-8	5553-5555	10	_	_	
38-9	5555-5556	-	_	_	
38-10	5556-5558	15	_	_	
38-11	5559-5560	M	_	_	
38-12	5561-5563	or	_	_	
38-13	5564-5568	less	_	_	
38-14	5569-5578	indicates	_	_	
38-15	5579-5587	covalent	_	_	
38-16	5588-5590	or	_	_	
38-17	5591-5600	extremely	_	_	
38-18	5601-5606	tight	_	_	
38-19	5607-5619	non-covalent	_	_	
38-20	5620-5627	binding	_	_	
38-21	5628-5629	.	_	_	
38-22	5630-5631	.	_	_	
38-23	5632-5633	.	_	_	
38-24	5634-5635	.	_	_	
38-25	5635-5636	"	_	_	
38-26	5637-5638	[	_	_	
38-27	5638-5642	0570	_	_	
38-28	5642-5643	]	_	_	
38-29	5644-5646	As	_	_	
38-30	5647-5649	is	_	_	
38-31	5650-5654	also	_	_	
38-32	5655-5664	disclosed	_	_	
38-33	5665-5667	in	_	_	
38-34	5668-5671	U.S	_	_	
38-35	5671-5672	.	_	_	

#Text=Pat.
39-1	5673-5676	Pat	_	_	
39-2	5676-5677	.	_	_	

#Text=No. 5,252,713, "During dialysis, non-covalently bound drug molecules are released over time from the protein and pass through a dialysis membrane, whereas covalently bound drug molecules are retained on the protein.
40-1	5678-5680	No	_	_	
40-2	5680-5681	.	_	_	
40-3	5682-5691	5,252,713	_	_	
40-4	5691-5692	,	_	_	
40-5	5693-5694	"	_	_	
40-6	5694-5700	During	_	_	
40-7	5701-5709	dialysis	_	_	
40-8	5709-5710	,	_	_	
40-9	5711-5725	non-covalently	_	_	
40-10	5726-5731	bound	_	_	
40-11	5732-5736	drug	_	_	
40-12	5737-5746	molecules	_	_	
40-13	5747-5750	are	_	_	
40-14	5751-5759	released	_	_	
40-15	5760-5764	over	_	_	
40-16	5765-5769	time	_	_	
40-17	5770-5774	from	_	_	
40-18	5775-5778	the	_	_	
40-19	5779-5786	protein	_	_	
40-20	5787-5790	and	_	_	
40-21	5791-5795	pass	_	_	
40-22	5796-5803	through	_	_	
40-23	5804-5805	a	_	_	
40-24	5806-5814	dialysis	_	_	
40-25	5815-5823	membrane	_	_	
40-26	5823-5824	,	_	_	
40-27	5825-5832	whereas	_	_	
40-28	5833-5843	covalently	_	_	
40-29	5844-5849	bound	_	_	
40-30	5850-5854	drug	_	_	
40-31	5855-5864	molecules	_	_	
40-32	5865-5868	are	_	_	
40-33	5869-5877	retained	_	_	
40-34	5878-5880	on	_	_	
40-35	5881-5884	the	_	_	
40-36	5885-5892	protein	_	_	
40-37	5892-5893	.	_	_	

#Text=An equilibrium constant of about 10-5 M indicates non-covalent binding.
41-1	5894-5896	An	_	_	
41-2	5897-5908	equilibrium	_	_	
41-3	5909-5917	constant	_	_	
41-4	5918-5920	of	_	_	
41-5	5921-5926	about	_	_	
41-6	5927-5929	10	_	_	
41-7	5929-5930	-	_	_	
41-8	5930-5931	5	_	_	
41-9	5932-5933	M	_	_	
41-10	5934-5943	indicates	_	_	
41-11	5944-5956	non-covalent	_	_	
41-12	5957-5964	binding	_	_	
41-13	5964-5965	.	_	_	

#Text=Alternatively, the protein may be subjected to denaturing conditions; e.g., by gel electrophoresis on a denaturing (SDS) gel or on a gel filtration column in the presence of a strong denaturant such as 6M guanidine.
42-1	5966-5979	Alternatively	_	_	
42-2	5979-5980	,	_	_	
42-3	5981-5984	the	_	_	
42-4	5985-5992	protein	_	_	
42-5	5993-5996	may	_	_	
42-6	5997-5999	be	_	_	
42-7	6000-6009	subjected	_	_	
42-8	6010-6012	to	_	_	
42-9	6013-6023	denaturing	_	_	
42-10	6024-6034	conditions	_	_	
42-11	6034-6035	;	_	_	
42-12	6036-6039	e.g	_	_	
42-13	6039-6040	.	_	_	
42-14	6040-6041	,	_	_	
42-15	6042-6044	by	_	_	
42-16	6045-6048	gel	_	_	
42-17	6049-6064	electrophoresis	_	_	
42-18	6065-6067	on	_	_	
42-19	6068-6069	a	_	_	
42-20	6070-6080	denaturing	_	_	
42-21	6081-6082	(	_	_	
42-22	6082-6085	SDS	_	_	
42-23	6085-6086	)	_	_	
42-24	6087-6090	gel	_	_	
42-25	6091-6093	or	_	_	
42-26	6094-6096	on	_	_	
42-27	6097-6098	a	_	_	
42-28	6099-6102	gel	_	_	
42-29	6103-6113	filtration	_	_	
42-30	6114-6120	column	_	_	
42-31	6121-6123	in	_	_	
42-32	6124-6127	the	_	_	
42-33	6128-6136	presence	_	_	
42-34	6137-6139	of	_	_	
42-35	6140-6141	a	_	_	
42-36	6142-6148	strong	_	_	
42-37	6149-6159	denaturant	_	_	
42-38	6160-6164	such	_	_	
42-39	6165-6167	as	_	_	
42-40	6168-6170	6M	_	_	
42-41	6171-6180	guanidine	_	_	
42-42	6180-6181	.	_	_	

#Text=Covalently bound drug molecules remain bound to the denatured protein, whereas non-covalently bound drug molecules are released and migrate separately from the protein on the gel and are not retained with the protein on the column."
43-1	6182-6192	Covalently	_	_	
43-2	6193-6198	bound	_	_	
43-3	6199-6203	drug	_	_	
43-4	6204-6213	molecules	_	_	
43-5	6214-6220	remain	_	_	
43-6	6221-6226	bound	_	_	
43-7	6227-6229	to	_	_	
43-8	6230-6233	the	_	_	
43-9	6234-6243	denatured	_	_	
43-10	6244-6251	protein	_	_	
43-11	6251-6252	,	_	_	
43-12	6253-6260	whereas	_	_	
43-13	6261-6275	non-covalently	_	_	
43-14	6276-6281	bound	_	_	
43-15	6282-6286	drug	_	_	
43-16	6287-6296	molecules	_	_	
43-17	6297-6300	are	_	_	
43-18	6301-6309	released	_	_	
43-19	6310-6313	and	_	_	
43-20	6314-6321	migrate	_	_	
43-21	6322-6332	separately	_	_	
43-22	6333-6337	from	_	_	
43-23	6338-6341	the	_	_	
43-24	6342-6349	protein	_	_	
43-25	6350-6352	on	_	_	
43-26	6353-6356	the	_	_	
43-27	6357-6360	gel	_	_	
43-28	6361-6364	and	_	_	
43-29	6365-6368	are	_	_	
43-30	6369-6372	not	_	_	
43-31	6373-6381	retained	_	_	
43-32	6382-6386	with	_	_	
43-33	6387-6390	the	_	_	
43-34	6391-6398	protein	_	_	
43-35	6399-6401	on	_	_	
43-36	6402-6405	the	_	_	
43-37	6406-6412	column	_	_	
43-38	6412-6413	.	_	_	
43-39	6413-6414	"	_	_	
